This company has shut down. Doloromics is no longer operating — its last tracked round was a Seed in 2022.
Explore the Startup GraveyardCapitalizing on our human data-guided target identification and validation platform, we are redefining the landscape of pain management.
Doloromics has raised $6.7M in total funding. The most recent round was Seed. The last funding was announced in February 2022.
Doloromics's investors include Mayfield Fund, Illumina Accelerator.
Doloromics is headquartered in Menlo Park, United States.
Capitalizing on our human data-guided target identification and validation platform, we are redefining the landscape of pain management.
Doloromics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Doloromics — Funding & Investors." VCBacked, February 1, 2022, https://www.vcbacked.co/company/doloromics. Accessed September 30, 2026.
VCBacked. (2022). Doloromics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/doloromics
{{cite web |title=Doloromics — Funding & Investors |url=https://www.vcbacked.co/company/doloromics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated